Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10M Buy
90,206
+7,138
+9% +$845K 0.72% 46
2025
Q4
$11.2M Buy
83,068
+63,640
+328% +$6.94M 0.82% 38
2025
Q3
$1.65M Buy
+19,428
New +$1.19M 0.13% 168

Other funds holding ABVX

Nicholas Investment Partners's ABVX Position: Q1 2026 in Review

Nicholas Investment Partners increased its Abivax (ABVX) stake by 8.6% in Q1 2026, buying an estimated $845K and bringing the position to 90,206 shares worth $10M. The position accounts for 0.72% of the portfolio, ranked #46.

Nicholas Investment Partners first reported a position in ABVX in Q3 2025 and has held it in 3 quarters since. The position peaked at $11.2M in Q4 2025. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

  • Nicholas Investment Partners held 90,206 shares of Abivax worth $10M as of Q1 2026.
  • Nicholas Investment Partners bought 7,138 Abivax shares in Q1 2026, an estimated $845K.
  • Abivax made up 0.72% of Nicholas Investment Partners's portfolio in Q1 2026, its #46 holding.
  • Nicholas Investment Partners first reported a position in Abivax in Q3 2025 and has held it in 3 quarters since.
  • Nicholas Investment Partners's Abivax position peaked at $11.2M in Q4 2025.
  • 254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on Nicholas Investment Partners's 13F filing for Q1 2026, filed 15 May 2026.